Altium Capital Management LLC Acquires 4,000 Shares of Savara Inc (NASDAQ:SVRA)

Altium Capital Management LLC increased its holdings in Savara Inc (NASDAQ:SVRA) by 0.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,579,000 shares of the company’s stock after buying an additional 4,000 shares during the quarter. Savara accounts for about 1.4% of Altium Capital Management LLC’s investment portfolio, making the stock its 28th largest position. Altium Capital Management LLC’s holdings in Savara were worth $4,848,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in SVRA. Marshall Wace LLP purchased a new position in shares of Savara during the 4th quarter valued at about $1,109,000. Jump Financial LLC purchased a new stake in Savara in the 4th quarter worth approximately $64,000. XTX Topco Ltd bought a new stake in Savara during the 4th quarter worth approximately $34,000. Barclays PLC lifted its holdings in Savara by 2.5% during the fourth quarter. Barclays PLC now owns 236,705 shares of the company’s stock valued at $728,000 after purchasing an additional 5,700 shares in the last quarter. Finally, F M Investments LLC bought a new position in shares of Savara in the fourth quarter worth approximately $250,000. 87.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on SVRA shares. JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. Finally, Wells Fargo & Company assumed coverage on shares of Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Stock Up 2.7 %

Shares of NASDAQ SVRA opened at $3.01 on Friday. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.31. The stock’s fifty day simple moving average is $2.73 and its two-hundred day simple moving average is $3.10. The stock has a market capitalization of $519.63 million, a PE ratio of -7.00 and a beta of 0.52. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. As a group, analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.